These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 35296994)

  • 1. Economic Evaluation of Sintilimab Plus Bevacizumab Versus Sorafenib as a First-line Treatment for Unresectable Hepatocellular Carcinoma.
    Zhou T; Cao Y; Wang X; Yang L; Wang Z; Ma A; Li H
    Adv Ther; 2022 May; 39(5):2165-2177. PubMed ID: 35296994
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma.
    Su D; Wu B; Shi L
    JAMA Netw Open; 2021 Feb; 4(2):e210037. PubMed ID: 33625508
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib for Patients With Unresectable or Metastatic Hepatocellular Carcinoma.
    Zhang X; Wang J; Shi J; Jia X; Dang S; Wang W
    JAMA Netw Open; 2021 Apr; 4(4):e214846. PubMed ID: 33825837
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study.
    Ren Z; Xu J; Bai Y; Xu A; Cang S; Du C; Li Q; Lu Y; Chen Y; Guo Y; Chen Z; Liu B; Jia W; Wu J; Wang J; Shao G; Zhang B; Shan Y; Meng Z; Wu J; Gu S; Yang W; Liu C; Shi X; Gao Z; Yin T; Cui J; Huang M; Xing B; Mao Y; Teng G; Qin Y; Wang J; Xia F; Yin G; Yang Y; Chen M; Wang Y; Zhou H; Fan J;
    Lancet Oncol; 2021 Jul; 22(7):977-990. PubMed ID: 34143971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness analysis of sintilimab plus bevacizumab biosimilar compared with lenvatinib as the first-line treatment of unresectable or metastatic hepatocellular carcinoma.
    Zhou T; Wang X; Cao Y; Yang L; Wang Z; Ma A; Li H
    BMC Health Serv Res; 2022 Nov; 22(1):1367. PubMed ID: 36397064
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atezolizumab and bevacizumab combination compared with sorafenib as the first-line systemic treatment for patients with unresectable hepatocellular carcinoma: A cost-effectiveness analysis in China and the United states.
    Wen F; Zheng H; Zhang P; Liao W; Zhou K; Li Q
    Liver Int; 2021 May; 41(5):1097-1104. PubMed ID: 33556230
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sintilimab Plus Bevacizumab Biosimilar Versus Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Cost-Effectiveness Analysis.
    Peng Y; Zeng X; Peng L; Liu Q; Yi L; Luo X; Li S; Wang L; Qin S; Wan X; Tan C
    Front Pharmacol; 2022; 13():778505. PubMed ID: 35222020
    [No Abstract]   [Full Text] [Related]  

  • 8. Cost-effectiveness analysis of sorafenib, lenvatinib, atezolizumab plus bevacizumab and sintilimab plus bevacizumab for the treatment of advanced hepatocellular carcinoma in China.
    Gong H; Ong SC; Li F; Weng Z; Zhao K; Jiang Z
    Cost Eff Resour Alloc; 2023 Mar; 21(1):20. PubMed ID: 37004046
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Promising first-line immuno-combination therapies for unresectable hepatocellular carcinoma: A cost-effectiveness analysis.
    Wen F; Huang P; Wu Q; Yang Y; Zhou K; Zhang M; Li Q
    Cancer Med; 2024 Aug; 13(16):e70094. PubMed ID: 39149756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness analysis of atezolizumab plus bevacizumab compared with sorafenib as first-line treatment in advanced hepatocellular carcinoma in Singapore.
    Chee CE; Khara JS; Cheong J; Fong J; Sivanesan S; Choy JY; Hu M; Viswambaram A; Toh HC
    Expert Rev Pharmacoecon Outcomes Res; 2024 Jun; 24(5):631-641. PubMed ID: 38776431
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness analysis of sintilimab plus IBI305 versus sorafenib for unresectable hepatic cell carcinoma in China.
    Xu Z; Ye ZM; Tang YK; Deng DF; Zhou Q; Fang M; Zhang YY; Li XP
    Cancer Med; 2023 Jul; 12(14):14871-14880. PubMed ID: 37434398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-Effectiveness Analysis of Five Systemic Treatments for Unresectable Hepatocellular Carcinoma in China: An Economic Evaluation Based on Network Meta-Analysis.
    Zhao M; Pan X; Yin Y; Hu H; Wei J; Bai Z; Tang W
    Front Public Health; 2022; 10():869960. PubMed ID: 35493395
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic evaluation of sintilimab plus chemotherapy vs. pembrolizumab plus chemotherapy for the treatment of first-line advanced or metastatic squamous NSCLC.
    Chen P; Wang X; Zhu S; Li H; Rui M; Wang Y; Sun H; Ma A
    Front Public Health; 2022; 10():956792. PubMed ID: 36016894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First-line systemic treatment strategies for unresectable hepatocellular carcinoma: A cost-effectiveness analysis.
    Wang L; Peng Y; Qin S; Wan X; Zeng X; Li S; Liu Q; Tan C
    PLoS One; 2023; 18(4):e0279786. PubMed ID: 37053300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-Effectiveness Analysis of Sintilimab Plus Chemotherapy in Advanced Non-Squamous Non-Small Cell Lung Cancer: A Societal Perspective.
    Li F; Chen Y; Xiao D; Jiang S; Yang Y
    Adv Ther; 2024 Apr; 41(4):1436-1449. PubMed ID: 38356107
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune Checkpoint Inhibitors Plus an Anti-VEGF Antibody as the First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Network Meta-Analysis and Cost-Effectiveness Analysis.
    Li L; Yang S; Chen Y; Tian L; He Y; Wu B; Dong D
    Front Pharmacol; 2022; 13():891008. PubMed ID: 35721168
    [No Abstract]   [Full Text] [Related]  

  • 17. The Cost Effectiveness of Donafenib Compared With Sorafenib for the First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma in China.
    Meng R; Cao Y; Zhou T; Hu H; Qiu Y
    Front Public Health; 2022; 10():794131. PubMed ID: 35433574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of sintilimab plus chemotherapy versus chemotherapy alone as first-line treatment of locally advanced or metastatic oesophageal squamous cell carcinoma.
    Liu L; Wang L; Chen L; Ding Y; Zhang Q; Shu Y
    Front Immunol; 2023; 14():1092385. PubMed ID: 36756110
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness analysis of sintilimab plus pemetrexed and platinum versus chemotherapy alone as first-line treatment in metastatic non-squamous non-small cell lung cancer in China.
    Liu H; Wang Y; He Q
    Health Econ Rev; 2022 Dec; 12(1):66. PubMed ID: 36581793
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapy or targeted therapy as the first-line strategies for unresectable hepatocellular carcinoma: A network meta-analysis and cost-effectiveness analysis.
    Liu K; Zhu Y; Zhu H
    Front Immunol; 2022; 13():1103055. PubMed ID: 36713376
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.